VNN

VNN is a biotechnology company focused on developing novel small molecule inhibitors targeting the Vanin-1 (VNN1) enzyme, also known as pantetheinase. The company's therapeutic approach centers on modulating the pantetheinase pathway to address oxidative stress and tissue inflammation, which are key drivers in various chronic diseases. VNN's primary research efforts are directed toward treating inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, as well as metabolic and fibrotic conditions like NASH and chronic kidney disease. By inhibiting Vanin-1, the company aims to restore cellular homeostasis and provide a new class of anti-inflammatory treatments for patients with high unmet medical needs.